Summary
Five healthy volunteers took 1.2 g rifampicin daily for 8 days, and before and afterwards each received hexobarbital (7.32 mg/kg) and tolbutamide (20 mg/kg) by i.v. infusion on two consecutive days. The plasma concentrations of the two drugs were determined during and after infusion. The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment. It was calculated that the metabolic clearance of hexobarbital had increased about three-fold and that of tolbutamide more than two-fold. Significant changes in the distribution kinetics of the two drugs were not observed. The results suggest that rifampicin is capable of inducing drug metabolism in man, which leads to an increased rate of elimination of drugs that undergo biotransformation in the liver.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Acocella, G., L. Bonollo, M. Garimoldi, M. Mainardi, T. Tenconi, F.B. Nicolis: Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut13, 47–53 (1972a)
Acocella, G., A. Lamarina, F.B. Nicolis, V. Pagani, G. Segre: Kinetic studies on rifampicin. II. Multicompartmental analysis of the serum, urine and bile concentrations in subjects treated for one week. Europ. J. clin. Pharmacol.5, 111–115 (1972b)
Boman, G.: Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. Europ. J. clin. Pharmacol.7, 217–225 (1974)
Bradley, S.E., F.J. Ingelfinger, G.P. Bradley: Hepatic circulation in cirrhosis of the liver. Circulation5, 419–429 (1952)
Branch, A.R., G.D. Shand, G.R. Wilkinson, A.S. Nies: Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. J. clin. Invest.53, 1101–1107 (1974)
Breimer, D.D.: Pharmacokinetics and biopharmaceutics of barbiturates and chloral hydrate in man. Ph.D.-thesis, Nijmegen, The Netherlands, (1974)
Breimer, D.D., J.M. van Rossum: Rapid and sensitive gas chromatographic determination of hexobarbital in plasma of man using a nitrogen detector. J. Chromatogr.88, 235–243 (1974)
Breimer, D.D., C. Honhoff, W. Zilly, E. Richter, J.M. van Rossum: Pharmacokinetics of hexobarbital in man after intravenous infusion. J. Pharmacokin. Biopharm.3, 1–11 (1975)
Bush, M.T., W.L. Weller: Metabolic fate of hexobarbital (HB). Drug Metab. Rev.1, 249–290 (1972)
Bush, M.T., T.C. Butler, H.L. Dickison: The metabolic fate of 5(1 - cyclo-hexen-1-yl)-1,5-dimethyl barbituric acid (hexobarbital, Evipal) and of 5-(1-cyclo-hexen-1-yl)-5-methyl barbituric acid (“Nor-Evipal”). J. Pharmacol. exp. Ther.108, 104–111 (1953)
Curci, G., N. Bergamini, F. Delli Veneri, A. Ninni, V. Nitti: Half-life of rifampicin after repeated administration of different doses in humans. Chemotherapia (Basel)17, 373–381 (1972)
Edwards, O.M., R.J. Cortenay-Evans, J.M. Galley, J. Hunter, A.D. Tait: Changes in cortisol metabolism following rifampicin therapy. Lancet1974 II, 549–551
Freij, H.H., F. Sudeney, D. Kranse: Vergleichende Untersuchungen über Stoffwechsel, Ausscheidung und Nachweis von Schlafmitteln aus der Barbitursäurereihe. Arzneimittel-Forsch.9, 294–297 (1959)
Gillette, J.R.: Factors affecting drug metabolism. In: Drug metabolism in man. Ann. N.Y. Acad. Sci.179, 43–66 (1971)
Hakim, J., G. Feldmann, J. Bucherot, P. Boivin, P. Guibout, B. Kreis: Effect of rifampicin, isoniazid and streptomycin on the human liver: a problem of enzyme induction. Gut12, 761 (1971)
Held, H., R. Eisert, H.F. von Oldershausen: Pharmakokinetik von Glymidine (Glycodiazin) und Tolbutamid bei akuten und chronischen Leberschäden. Arzneimittel-Forsch. (Drug Res.)23, 1801–1807 (1973)
Jezequel, A.M., F. Orlandi, L.T. Tenconi: Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guineapig hepatocytes. Gut12, 984–987 (1971)
Loo, J.C.K., S. Riegelman: Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i.v. infusion. J. pharm. Sci.59, 53–55 (1970)
Maggi, N., S. Furesz, R. Pallanza, G. Pelizza: Rifampicin desacetylation in the human organism. Arzneimittel-Forsch.19, 651–654 (1969)
Melikian, V., J.D. Eddy, A. Paton: The stimulant effect of drugs on indocyanine green clearance by the liver. Gut13, 755–758 (1972)
Michot, F., M. Bürgi, J. Büttner: Rimactan (Rifampicin) und Antikoagulantientherapie. Schweiz. med. Wschr.100, 583–587 (1970)
Nelson, E., J. O'Reilly, Th. Chulski: Determination of carboxytolbutamide in urine. Clin. chim. Acta5, 774–776 (1960)
Nocke-Fink, L., H. Breuer, D. Reimers: Wirkung von Rifampicin auf den Menstruationszyklus und die Östrogenausscheidung bei Einnahme oraler Kontrazeptiva. Dtsch. med. Wschr.98, 1521–1523 (1973)
Remmer, H., B. Schoene, R. Fleischmann, H. Held: Induction of the unspecific microsomal hydroxylase in the human liver. In: The liver. Quantitative aspects of structure and function. p. 232, Basel: Karger 1973
Riegelman, S., M. Rowland: Effect of route of administration on drug disposition. J. Pharmacokin. Biopharm.1, 419–434 (1973)
Rossum, J.M. van: Significance of pharmacokinetics for drug design and the planning of dosage regimes. In: Drug design, vol. I, pp. 469–521, New York: Academic Press, 1971
Rowland, M., L.Z. Benet, G.G. Graham: Clearance concepts in pharmacokinetics. J. Pharmacokin. Biopharm.1, 123–136 (1973)
Scheuer, P.J., S. Lal, J.A. Summerfield, S. Sherlock: Rifampicin hepatitis. Lancet1974 I, 421–425
Schoene, B., R.A. Fleischmann, H. Remmer, H.F. von Oldershausen: Determination of drug metabolizing enzymes in needle biopsies of human liver. Europ. J. clin. Pharmacol.4, 65–73 (1973)
Scholtan, W.: Die Bindung der Sulfonamide an Eiweißkörper. 6. Bestimmung der Eiweißbindung von Sulfonamiden mittels der Ultrazentrifuge und mittels Gelfiltration. Arzneimittel-Forsch.15, 1433–1441 (1965)
Spingler, H.: Über eine Möglichkeit zur colorimetrischen Bestimmung von N-(4-Methyl-benzolsulfonyl)-N'-butyl-Harnstoff in Serum. Klin. Wschr.10, 533–535 (1957)
Südhof, H., W. Eger, S. Altenburg, G. Schumacher: Blutzuckersenkung durch orale Antidiabetica und Verhalten des N-(4-Methyl-benzolsulfonyl)-N'-butyl-Harnstoffes im Serum in Abhängigkeit von der Leberfunktion. Arzneimittel-Forsch. (Drug Res.)7, 438–442 (1958)
Thomas, R.C., G.J. Ikeda: The metabolic fate of tolbutamide in man and in the rat. J. med. Chem.9, 507–518 (1966)
Thomson, P.D., K.L. Melman, J.A. Richardson, K. Cohn, W. Steinbrunn, R. Cudihee, M. Rowland: Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. Ann int. Med.78, 499–508 (1973)
Tsukamoto, H., S. Toki, K. Kaneda: Detection of hydroxyl derivatives from urine of men administered ethyl-hexabital and methyl-hexabital by buffered paper chromatography. Chem. pharm. Bull.6, 625–626 (1957)
Virtanen, S., E. Tala: Serum concentration of rifampicin after oral administration. Clin. Pharmacol. Ther.16, 817–820 (1974)
Zilly, W., D.D. Breimer, E. Richter: Unpublished investigation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zilly, W., Breimer, D.D. & Richter, E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 9, 219–227 (1975). https://doi.org/10.1007/BF00614021
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00614021